In particular, we did not examine whether the mutations addressed in our cancer cell lines—the TP53 mutation in CAOV-3, and the CDKN2A mutation in SKOV-3—possibly modulate the activation of the HH pathway. The gene discussed is CDKN2A; the disease is cancer.